|

Eribulin Mesylate Clinical Trials

2 actively recruiting trials across 1 location

Also known as: B1939 Mesylate, E7389, ER-086526 Mesylate, Halaven, Halichondrin B Analog

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Seoul National University Hospital1
  • National Cancer Institute (NCI)1

Indications

  • Cancer2
  • Refractory Urothelial Carcinoma1
  • Refractory Bladder Urothelial Carcinoma1
  • Metastatic Bladder Urothelial Carcinoma1
  • Stage IV Bladder Cancer AJCC v81

Other1 trial

Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
Phase 2

Kingman, Arizona1 trial

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Kingman Regional Medical Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.